Conditions: MDD
Keywords: schizophrenia Major depressive disorder Anxiety Symptoms School, Work environment Mental Disorders Psychotic Disorders antipsychotic
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 48
Healthy volunteers: no

Brief summary:
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response in a school or work environment.

Detailed description:

Arms:
arm 1: Up to 3mg/day, once daily dose, tablets, orally

Interventions: intervention 1: Brexpiprazole
Intervention descriptions: intervention 1: Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally

Protocol document: